A new paradigm for TB drug development is needed—one that focuses on developing not just drugs but entire drug regimens.
The Critical Path to TB Drug Regimens (CPTR) works to tackle the challenges facing TB drug development. This includes gaining support for a paradigm of drug development that enables promising combinations of drugs to be tested and developed together to create entirely new multi-drug treatments. This approach is expected to reduce the time it takes to develop an innovative regimen from decades to years. CPTR is made possible by unprecedented collaboration among pharma companies and strong commitments from public and private partners around the world. More >
by Patrick Adams Originally published by New York Times on January 5, 2015 On a recent morning at Persahabatan Hospital in East Jakarta, patients, some from remote villages accessible only by boat, gathered in a waiting room. Nearby, lab technicians used new diagnostic technology to test sputum samples for multidrug-resistant tuberculosis, in an effort to
Day One: September 24, 2014 See the Workshop Overview See the Session Recaps and Presentations from Day 2 Welcome – Objective of Meeting Speaker: Jan Gheuens, Bill & Melinda Gates Foundation Jan Gheuens summarized the progress of CPTR since its inception and stressed the importance of a coordinated approach toward regimen development. He discussed the
These stories link to the WHO's Working Group on New TB Drugs